Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hodgkinson

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Blood|January 1, 1991
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoidesS J Knox, R Levy, S Hodgkinson, et al.
Annals of Neurology|January 1, 1996
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task ForceD H Miller, P S Albert, F Barkhof, et al.
Photochemistry and Photobiology|July 16, 2017
Early Life UV and Risk of Basal and Squamous Cell Carcinoma in New South Wales, AustraliaAnne Kricker, Marianne Weber, Freddy Sitas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 11, 2019
High Ambient Solar UV Correlates with Greater Beta HPV Seropositivity in New South Wales, AustraliaAnne Kricker, Marianne F Weber, Nicole Brenner, et al.
Neurology|August 1, 1997
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trialB W van Oosten, M Lai, S Hodgkinson, et al.
European Journal of Neurology|January 20, 2016
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosisT Spelman, L Mekhael, T Burke, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 15, 2024
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programmeT A Hardy, P Aouad, M H Barnett, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Blood|January 1, 1991
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoidesS J Knox, R Levy, S Hodgkinson, et al.
Annals of Neurology|January 1, 1996
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task ForceD H Miller, P S Albert, F Barkhof, et al.
Photochemistry and Photobiology|July 16, 2017
Early Life UV and Risk of Basal and Squamous Cell Carcinoma in New South Wales, AustraliaAnne Kricker, Marianne Weber, Freddy Sitas, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 11, 2019
High Ambient Solar UV Correlates with Greater Beta HPV Seropositivity in New South Wales, AustraliaAnne Kricker, Marianne F Weber, Nicole Brenner, et al.
Neurology|August 1, 1997
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trialB W van Oosten, M Lai, S Hodgkinson, et al.
European Journal of Neurology|January 20, 2016
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosisT Spelman, L Mekhael, T Burke, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 15, 2024
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programmeT A Hardy, P Aouad, M H Barnett, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
Pageof 5